LIXT LIXTE BIOTECHNOLOGY HOLDINGS, INC.
Price Chart
Executive Summary
Lixte Biotechnology is raising approximately $16.6 million in gross proceeds through a registered direct offering of 2,366,503 shares of common stock and 258,859 pre-funded warrants at $6.31 per share/warrant, priced at a ~10.4% discount to the $7.04 last sale price on June 2, 2026. The offering represents ~19% dilution to existing shareholders (pro forma shares outstanding increase from 12.65M to ~15.28M). Proceeds are earmarked for working capital and clinical development of lead compound LB-100, but the company remains pre-revenue with a going-concern qualification from its auditor.
Actionable Insight
The dilutive offering at a discount signals near-term capital needs and likely overhang. Monitor for further dilution risk given the going-concern qualification and pre-revenue status. The colorectal trial hold adds pipeline uncertainty. Watch for IRB decision on the SAEs and any subsequent clinical data updates.
Key Facts
- Offering of 2,366,503 shares of common stock and 258,859 pre-funded warrants at $6.31 per unit
- Gross proceeds of approximately $16,566,027.20; net proceeds same amount as placement agent fees are $0
- Pricing represents a ~10.4% discount to the $7.04 last sale price on June 2, 2026
- Pro forma shares outstanding increase from 12,653,444 to 15,278,806 (assuming exercise of pre-funded warrants), a ~20.7% increase
- Net tangible book value per share increases from $0.79 to $1.80; new investors face dilution of $4.51 per share
- Company has a going-concern qualification from its auditor (Weinberg & Company, P.A.) for fiscal year ended December 31, 2024
- No revenue-generating operations; company is a clinical-stage biopharmaceutical firm
- Colorectal cancer clinical trial (NCT06012734) on hold due to two serious adverse events (SAEs) under IRB investigation
- Proceeds to be used for working capital and clinical development of LB-100
- Offering closed on June 4, 2026, with no placement agent fees
Financial Impact
~$16.6M gross proceeds raised at a ~10.4% discount to market; ~20.7% dilution to existing shareholders
Risk Factors
- Significant dilution (~20.7%) to existing shareholders from this offering
- Going-concern qualification from auditor indicates substantial doubt about ability to continue as a going concern
- Colorectal cancer clinical trial on hold due to two serious adverse events; outcome of IRB review uncertain
- Pre-revenue company with no guarantee of future revenue or profitability
- Management has broad discretion over use of proceeds; no specific allocation provided
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 424B5 Filing (Primary) | 0001493152-26-027286 |
| Document: 0001493152-26-027286-index-headers.html | 0001493152-26-027286 |
| Document: 0001493152-26-027286-index.html | 0001493152-26-027286 |
| Document: 0001493152-26-027286.txt | 0001493152-26-027286 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 12, 2026
2d ago
|
Press Release
| $7.20 awaiting T+5 | awaiting T+5 | — | $6.19 (−13.97%) |
|
Jun 4, 2026
10d ago
|
8-K
| $6.83 awaiting T+5 | awaiting T+5 | — | $6.19 (+9.37%) |
|
Jun 4, 2026
10d ago
|
424B5
| $7.06 awaiting T+5 | awaiting T+5 | — | $6.19 (+12.32%) |
|
Jun 1, 2026
13d ago
|
8-K
| $7.21 $7.00 | ▼ −2.91% | ▼ −0.16% | $6.19 (−14.15%) |
|
May 14, 2026
4w ago
|
Press Release
| $5.16 $5.88 | ▲ +13.95% | ▲ +12.99% | $6.19 (+19.96%) |
|
Apr 17, 2026
8w ago
|
8-K
| $3.44 $3.80 | ▲ +10.47% | ▲ +9.55% | $6.19 (+79.94%) |
|
Apr 13, 2026
8w ago
|
Press Release
| $2.93 $3.44 | ▲ +17.41% | ▲ +14.11% | $6.19 (+111.26%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access